Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.71 |
| ▸ | GBA1 | P04062 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | PDE5A | O76074 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.53 |
| ▸ | LATS1 | O95835 | 1/20 | 0.53 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.53 |
| ▸ | ACP1 | P24666 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748376 | 0.84 | MAPK1 (0.74) | MAPK1GBA1ALDH1A1PDE5AKMT2A | |
| SCHEMBL17799977 | 0.84 | GBA1 (0.54) | MAPK1GBA1PDE5AMEN1KMT2A | |
| SCHEMBL23723436 | 0.84 | TLR9 (0.72) | MAPK1GBA1ALDH1A1LMNAHPGD | |
| SCHEMBL30125496 | 0.84 | TLR9 (0.72) | MAPK1GBA1ALDH1A1LMNAHPGD | |
| SCHEMBL16404321 | 0.83 | MAPK1 (0.82) | MAPK1GBA1ALDH1A1LMNAHPGD | |
| SCHEMBL23723245 | 0.83 | PDE5A (0.53) | MAPK1GBA1ALDH1A1PDE5AMEN1 | |
| SCHEMBL3459468 | 0.83 | MAPK1 (0.82) | MAPK1GBA1ALDH1A1LMNAHPGD | |
| SCHEMBL17800078 | 0.81 | ACP1 (0.59) | GBA1PDE5AMEN1KMT2AACP1 | |
| SCHEMBL30125328 | 0.80 | TLR9 (0.63) | MAPK1GBA1ALDH1A1LMNAMEN1 | |
| SCHEMBL23723445 | 0.80 | TLR9 (0.63) | MAPK1GBA1ALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | MAPK1 3295/4885GBA1 1282/4885ALDH1A1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.